Analysts expect that Rubius Therapeutics Inc (NASDAQ:RUBY) will report ($0.36) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Rubius Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.27). The firm is expected to announce its next quarterly earnings results on Friday, November 30th.
According to Zacks, analysts expect that Rubius Therapeutics will report full year earnings of ($1.70) per share for the current fiscal year, with EPS estimates ranging from ($2.61) to ($1.03). For the next financial year, analysts forecast that the business will report earnings of ($1.50) per share, with EPS estimates ranging from ($1.90) to ($0.99). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Rubius Therapeutics.
Rubius Therapeutics (NASDAQ:RUBY) last released its earnings results on Friday, August 31st. The company reported ($3.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($2.73). During the same period in the previous year, the company posted ($1.25) EPS.
A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They set a “buy” rating and a $40.00 price objective for the company. Leerink Swann assumed coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They set an “outperform” rating for the company. Morgan Stanley assumed coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They set an “overweight” rating and a $37.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They set an “overweight” rating for the company.
In other Rubius Therapeutics news, Director Francis M. Cuss purchased 10,000 shares of Rubius Therapeutics stock in a transaction dated Friday, July 20th. The stock was acquired at an average price of $23.00 per share, for a total transaction of $230,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Rubius Therapeutics stock traded up $0.07 during trading on Friday, hitting $21.06. The stock had a trading volume of 320 shares, compared to its average volume of 128,838. Rubius Therapeutics has a 12 month low of $19.67 and a 12 month high of $33.01.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
Featured Article: Closed-End Mutual Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.